137624-14-7

Basic information

• Product Name: Mesatlantin C
• Synonyms: Mesatlantin C;(3aS,4aR,6aS,9aS,9bR)-5,6,6a,7,9a,9b-Hexahydro-1,4a-dimethyl-7-methylene-3H-oxireno[8,8a]azuleno[4,5-b]furan-8(4aH)-one
• CAS NO: 137624-14-7
• Molecular Formula: C₁₅H₁₈O₃
• Molecular Weight: 246.3
• Mol File: 137624-14-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Mesatlantin C(CAS DataBase Reference)
• NIST Chemistry Reference: Mesatlantin C(137624-14-7)
• EPA Substance Registry System: Mesatlantin C(137624-14-7)

Safety Data

• Hazardous Substances Data: 137624-14-7(Hazardous Substances Data)

Usage

Uses

Mesatlantin C is a sesquiterpene lactone extracted from Artemisia mesatlantica, and is a byproduct in the synthesis of Arglabin, an anti-cancer drug.

Upstream product

• 81066-45-7 kauniolide 
• 503551-53-9 parthenolide 
• 68370-47-8 (3aS,9R,9aS,9bS)-9-hydroxy-6,9-dimethyl-3-methylene-3a,4,5,7,8,9,9a,9b-octahydroazuleno[4,5-b]furan-2(3H)-one 
• 1343403-10-0 (1R,3aR,4aS,6aS,9aS,9bS)-1-hydroxy-1,4a-dimethyl-7-methyleneoctahydro-1H-oxireno[2',3':8,8a]azuleno[4,5-b]furan-8(4aH)-one 

Downstream Products

• 1370045-04-7 2-({[(3aR,4aS,6aS,7S,9aS,9bR)-1,4a-dimethyl-8-oxo-4a,5,6,6a,7,8,9a,9b-octahydro-3H-oxireno[8,8a]azuleno[4,5-b]furan-7-yl]methyl}thio)benzoic acid 
• 6831-14-7 arborescin 
• 36416-50-9 3α,4α-epoxyarglabin 
• 36416-50-9 3β,4β-epoxyarglabin 

Relevant articles and documents

Chamomile lactone derivative as well as preparation method and application thereof (by machine translation)

The invention relates to the technical field of organic synthesis, in particular to a small white chrysanthemum lactone derivative and a preparation method and application thereof. To the invention, small white chrysanthemum is used as the original main raw material, 11 small white chrysanthemum lactone derivatives are synthesized through a series of chemical reactions, and the derivatives have certain anti-proliferative activity on glioblastoma cells. The invention also proves that the deuterated derivative DMAPAPAPAPAPT-D6 can significantly induce accumulation of active oxygen of glioblastoma cells, thereby leading DNA damage in glioblastoma cells. Furthermore, DMAPAPAPAPAPT-D6 promotes exogenous apoptosis mediated by the death receptor of caspase, indicating DNA damage induced by DMAPAPAPAPAPT-D6 inducible glioblastoma apoptosis. , ROS accumulation caused by DMAPAPAPAPAPT-D6 treatment leads DNA damage and death receptor-mediated apoptosis, which indicates that DMAPAPAPAPAPT-D6 with novel ingredients has therapeutic potential for treating glioblastoma and can be applied to preparation of drugs for treating glioblastoma. (by machine translation)

USES OF SESQUITERPENE LACTONE COMPOUNDS AND THEIR DERIVATIVES IN DRUGS PREPARATION

The present invention relates to the uses of sesquiterpene lactone compounds and their derivatives in preparing drugs. It belongs to the field of drug technology, specifically relates to the uses of the compounds of Formula (I) in preparing the drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.

Sesquiterpene lactones and their derivatives inhibit high glucose-induced NF-κB activation and MCP-1 and TGF-β1 expression in rat mesangial cells

Diabetic nephropathy (DN) is one of the most common and serious chronic complications of diabetes mellitus, however, no efficient clinical drugs exist for the treatment of DN. We selected and synthesized several sesquiterpene lactones (SLs), and then used the MTT assay to detect rat mesangial cells (MCs) proliferation, ELISA to measure the expression level of monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta (TGF-β1) and fibronectin(FN), real-time fluorescent quantitative PCR analysis to measure the MCP-1 and TGF-β1 gene expression, western blot to detect the level of IκBα protein and EMSA to measure the activation of nuclear factor kappa B (NF-κB). We discovered that SLs, including parthenolide (PTL), micheliolide (MCL), arglabin, and isoalantolactone (IAL), as well as several synthetic analogs of these molecules, could effectively attenuate the high glucose-stimulated activation of NF-κB, the degradation of IκBα, and the expression of MCP-1, TGF-β1 and FN in rat mesangial cells (MCs). These findings suggest that SLs and their derivatives have potential as candidate drugs for the treatment of DN.